![ISPOR 2024 May 5-8, 2024 | Atlanta, GA, USA. Early Registration Rate expires March 28.]({"type":"image" , "src" : "/sda/112343/IJME-March-May.jpg"})
Figures & data
Table 1. Patient characteristics at baseline (insulin initiation).
Table 2. Diabetes-related resource utilization and frequency of use by country in INSTIGATE in the 6 months prior to the baseline and 12-month visits.
Table 3. Diabetes-related resource utilization and frequency of use by country in TREAT in the 6 months prior to the baseline and 12-month visits.
Table 4. Total per-patient direct costs related to diabetes care up to 12 months in the INSTIGATE and TREAT studies.
Figure 1. (a) Itemized mean costs for diabetes care over 12 months in Germany in INSTIGATE. (b) Itemized mean costs for diabetes care over 12 months in Spain in INSTIGATE. (c) Itemized mean costs for diabetes care over 12 months in Sweden in TREAT. Total patient numbers for Germany were 155 at insulin initiation, 151 at 6 months, and 153 at 12 months. Total patient numbers for Spain were 172 at insulin initiation, 172 at 6 months, and 172 at 12 months. Total patient numbers for Sweden were 115 at insulin initiation, 109 at 6 months, and 104 at 12 months.
Figure 2. (a) Itemized mean costs for diabetes care over 12 months in Greece in INSTIGATE. (b) Itemized mean costs for diabetes care over 12 months in Greece in TREAT. Total patient numbers for INSTIGATE were 237 at insulin initiation, 237 at 6 months, and 237 at 12 months. Total patient numbers for TREAT were 147 at insulin initiation, 142 at 6 months, and 134 at 12 months.
